High dose iron regimen improves outcomes in dialysis patients, UK study findsBMJ 2018; 363 doi: https://doi.org/10.1136/bmj.k4581 (Published 30 October 2018) Cite this as: BMJ 2018;363:k4581
- Jacqui Wise
Patients undergoing kidney dialysis who were given a high dose regimen of intravenous iron needed fewer blood transfusions and lower doses of erythropoiesis stimulating agent (ESA) to maintain target haemoglobin levels than those in a low dose group, a large UK trial has found.
In addition, a high dose iron regimen seemed to protect against recurrent events, including admission for heart failure. The high dose regimen was also not associated with a greater risk of infection, in the study published in the New England Journal of Medicine.1
Safety concerns have previously arisen about using higher doses of ESAs to elevate haemoglobin levels, as cardiovascular toxic effects have been observed in trials.